Additional Information
Market: NYSE
Sector: Pharmaceuticals
EPIC: MRK
1 year chart
1 day chart
Merck & Co
www.merck.com

Merck & Co., Inc. is a research- driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health, directly and through its joint ventures.

Merck Q3 earnings edge up despite decline in sales

26th Oct 2012, 9:10 am by Joyanta Acharjee
The company is the maker of the asthma and allergy pill Singulair as well as Januvia, used in the treatment of diabetes. The company is the maker of the asthma and allergy pill Singulair as well as Januvia, used in the treatment of diabetes.

Drugmaker Merck & Co. (NYSE:MRK) Friday posted a 2 per cent rise in third-quarter earnings as reduced spending on overheads offset lower sales caused by new generic competition for its key Singulair drug.

The company is the maker of the asthma and allergy pill Singulair as well as Januvia, used in the treatment of diabetes.

For the three months ended September 30, net income was $1.73 billion, or 56 cents per share, up from $1.69 billion, or 55 cents from a year earlier.

Excluding charges, net income was $2.93 billion, or 95 cents per share, 2 cents more than analysts expected.

Revenue was $11.5 billion, down 4 per cent. Analysts had expected revenue of $11.57 billion.

"Our strong global sales this quarter offset the impact of the Singulair patent expiry in the U.S.," said Merck chairman and CEO Kenneth C. Frazier said. 

"We will continue to drive value for our customers and shareholders through Merck’s four-part strategy of executing on our core business, expanding geographically in high-growth markets, extending our complementary businesses and excelling at managing our costs while investing for growth. 

"With our robust pipeline, we remain on target to submit multiple new products for marketing approval between now and the end of 2013, including suvorexant for insomnia, odanacatib for osteoporosis and Tredaptive for multiple lipid parameters."

As it came off patent, sales of asthma and allergy pill Singulair dropped 55 per cent to $602 million.

Januvia sales rose 15 per cent to $975 million. Sales of Gardasil, a vaccine against HPV, rose 31 per cent to $581 million.

Sales increased for cholesterol drug Zetia, diabetes drug Janumet, shingles vaccine Zostavax and HIV drug Isentress. Sales decined for anti-inflammatory drug Remicade, cholesterol drug Vytorin and hypertension drugs Cozaar and Hyzaar.

Merck's animal health revenues declined 1 per cent to $815 million and consumer care sales rose 7 per cent to $451 million.

As with other pharma companies, Merck is facing sales erosion from patent expirations for top-selling drugs. 

The company also working to bring new products to the market to help offset revenue lost to expired patents. Merck recently presented positive results from clinical trials of experimental treatments for insomnia and osteoporosis.

Merck also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here